Pipendoxifene

DB05414InvestigationalSmall molecule

ER modulator, ERA-923(Pipendoxifene) is a estrogen receptor modulator being evaluated for the treatment of breast cancer. Pipendoxifene is a new 2-phenyl indole selective estrogen receptor modulators (SERM )that exhibits an...

Mechanism: ERA-923 inhibits estrogen-stimulated growth associated with cytostasis. It has been shown to have a potent, selective oestrogen modulating effect, with few uterine side-effects.
Curator reviewed
Primary indication: Investigated for use/treatment in breast cancer.Curator reviewed
Formula / weight: C₂₉H₃₂N₂O₃ · 456.576 g/mol (avg)
Code names: ERA-923

Resolves to

Compound

UNIITPC5Q8496GCAS198480-55-6ChEMBLCHEMBL44426PubChem6433099

Structure

InChIKeyJICOGKJOQXTAIP-UHFFFAOYSA-NSMILESCC1=C(N(CC2=CC=C(OCCN3CCCCC3)C=C2)C2=C1C=C(O)C=C2)C1=CC=C(O)C=C1

Targets

Q92731ESR2P03372ESR1Q81ZL8Integrase, catalytic core

What you can answer from here — as of January 29, 2025

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with Pipendoxifene, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account